+67.8%
TEAM vs MRNA
+794.5%
-726.7%
-87.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.2% | -4.8% | +0.6% | -3.8% |
| 7D | -11.4% | -20.9% | +9.5% | -9.5% |
| 30D | -37.1% | -13.3% | -23.8% | -36.6% |
| 3M | -17.1% | +212.6% | -229.7% | -31.9% |
| 6M | +51.0% | +309.0% | -258.0% | +18.9% |
| YTD | -16.7% | +567.3% | -584.0% | -39.9% |
| 1Y | -9.2% | +689.7% | -698.9% | -36.3% |
| 3Y | -27.0% | +157.4% | -184.4% | -42.7% |
| 5Y | -69.4% | -21.7% | -47.6% | -73.1% |
| All | +67.8% | +794.5% | -726.7% | +24.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling